BNTC (Benitec Biopharma) YoY EBITDA Growth: 30.89% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $13.48
View Full Analysis

What is Benitec Biopharma YoY EBITDA Growth?

Benitec Biopharma BNTC +3.22% 34 YoY EBITDA Growth is 30.89% as of Mar. 2026. GuruFocus rates BNTC with a GF Score™ of 34/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Benitec Biopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 30.89%.

Benitec Biopharma's EBITDA per Share for the three months ended in Mar. 2026 was $-0.27.

Benitec Biopharma YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma YoY EBITDA Growth Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.65 30.46 63.51 91.06 5.22

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.93 -11.85 -14.22 0.00 30.89
BNTC
34GF Score
Benitec Biopharma Inc BNTC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Benitec Biopharma's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-1.143--1.206)/ | -1.206 |
=5.22 %

Benitec Biopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.273--0.395)/ | -0.395 |
=30.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 30.89% mean?
Benitec Biopharma (BNTC) has a YoY EBITDA Growth of 30.89% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Benitec Biopharma and its competitors.
Is Benitec Biopharma's YoY EBITDA Growth too high?
Benitec Biopharma's current YoY EBITDA Growth is 30.89%. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's YoY EBITDA Growth compare to EDIT and AUTL?
Benitec Biopharma's YoY EBITDA Growth of 30.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Benitec Biopharma and its competitors. Benitec Biopharma's current YoY EBITDA Growth is 30.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current YoY EBITDA Growth of 30.89%. The current YoY EBITDA Growth is 30.89%. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current YoY EBITDA Growth is 30.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.48
Price